All In Biotech

NDA 211379 · Dexcel

Hemady

Dexamethasone · Oral · Corticosteroid

Orphan

Last checked: Nov 19, 2026Latest source record: Jun 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Oct 3, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4,222

936 Phase 3, 495 recruiting

FAERS reports

295,320

250,048 serious, 48,061 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 9, 2026.

HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM). HEMADY is a corticosteroid indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma. (‎ 1 )

Mechanism: Dexamethasone is a corticosteroid with anti-inflammatory effects and low mineralocorticoid activity. The precise mechanism of action in multiple myeloma is unknown. Dexamethasone induces apoptosis of multiple myeloma cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 3, 2019 Original approval · New Combination and New Formulation or New Manufacturer OrphanLabelLetterReview
1 products under this application
  • HEMADY · DEXAMETHASONE 20MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexamethasone" as an intervention, any sponsor and status, largest first.

All 4,222 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use22,663
  • fatigue17,495
  • diarrhoea17,302
  • plasma cell myeloma14,405
  • nausea14,168
  • pneumonia13,816
  • death13,371
  • drug ineffective13,171
  • neutropenia11,780
  • pyrexia11,104
  • thrombocytopenia10,770
  • dyspnoea10,383

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,561
20052,135
20061,096
2007875
20081,308
20091,923
20103,580
20115,377
20126,679
20136,720
20148,343
201517,378
201615,820
201717,840
201823,304
201923,239
202025,159
202128,926
202227,281
202324,140
202421,442
202518,425
202612,767

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Hemady (Dexamethasone)

2024 spending

$120K

Beneficiaries

264

634 claims

Per beneficiary

$456

$27.32 per unit

View as table
YearSpending
2020$2,260
2021$68,013
2022$134,321
2023$159,328
2024$120,339

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,423 on PubMed

Sponsor: Dexcel

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.